A Study of Patients With HER2-Positive Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00105456
First received: March 14, 2005
Last updated: May 4, 2010
Last verified: May 2010

March 14, 2005
May 4, 2010
March 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00105456 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Patients With HER2-Positive Metastatic Breast Cancer
registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer

This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients from managed care organizations, community physicians or practices, and academic centers.

Breast Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1000
May 2009
Not Provided

Inclusion Criteria:

  • Signed Informed Consent document (unless the IRB has granted a waiver of consent)
  • Signed Authorization for the Use and Disclosure of Health Information document
  • HER2-positive breast cancer
  • Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment
  • Availability of cancer-specific historical data points in the patient's medical records

Exclusion Criteria:

  • There are no exclusion criteria for participation in this trial
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00105456
H2757n
Not Provided
Clinical Trials Posting Group, Genentech, Inc.
Genentech
Not Provided
Study Director: Isaiah Dimery, M.D. Genentech
Genentech
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP